Physician profile
Laura E Durling
NPI 1689968133
$4,499.34
in general payments reported to CMS, 2019-2025
42 companies · $860 in 2025
The $860 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $313 · 2021: $332 · 2022: $730 · 2023: $535 · 2024: $1,077 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $831.78 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $763.01 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $499.07 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $330.31 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $237.77 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Dexcom, INC. | $207.48 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $176.03 | 2022-2025 | |
| Glaxosmithkline, LLC. | $140.74 | 2022-2025 | Shingrix, Arexvy |
| Ucb, INC. | $125.00 | 2019 | |
| Abbott Laboratories | $112.50 | 2020-2023 | Freestyle Libre 3 |
| Pfizer INC. | $103.60 | 2019-2025 | |
| Exact Sciences Corporation | $90.19 | 2024-2025 | Cologuard Collection Kit |
| Janssen Biotech, INC. | $73.74 | 2022-2025 | Erleada |
| Janssen Pharmaceuticals, INC | $69.14 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.72 | 2022-2025 | Jardiance |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Durling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.